CROSSJECT Unveils 2024 Annual Financial Report for Investors

Author: Dylan Bailey Updated: 04-30-2025 12:04 PM

Introduction to CROSSJECT's Annual Financial Report

The annual financial report is a crucial document that provides insights into a company's performance and strategy. CROSSJECT, a pioneering pharmaceutical company, has just released its financial report for 2024, marking an important milestone in its ongoing journey.

Overview of CROSSJECT

CROSSJECT SA (Euronext: ALCJ) is an emerging pharmaceutical company known for its groundbreaking work in the development and registration of ZEPIZURE®, a life-saving emergency treatment for epilepsy crises. The company is not only committed to improving epileptic care but is also at the forefront of developing various emergency medications.

The ZEPIZURE® Breakthrough

ZEPIZURE® is designed to offer immediate relief during epileptic seizures, utilizing an award-winning needle-free injector known as ZENEO®. This innovative device allows individuals, even those without medical training, to administer an intramuscular injection quickly and efficiently, whether on bare skin or through clothing, offering a significant improvement in emergency medical response.

Financial Highlights from the 2024 Report

CROSSJECT's 2024 report presents notable financial achievements and insights, illustrating the company's robust growth trajectory. The firm successfully secured a significant contract worth 60 million dollars with the U.S. Biomedical Research and Development Authority (BARDA), aimed at advancing the research and development of ZEPIZURE® and other related products.

Future Developments and Additional Products

Beyond ZEPIZURE®, CROSSJECT is actively pursuing the development of additional treatments for critical health issues including allergic shocks, adrenal insufficiencies, opioid overdoses, and asthma attacks. This diverse pipeline showcases the company's commitment to addressing multiple urgent healthcare needs.

Investor Relations and Contact Information

Investors looking for detailed insights or further information are encouraged to connect with the Investor Relations team. As CROSSJECT continues to innovate and expand its product offerings, staying informed through its financial reports and updates is essential for current and prospective investors.

For inquiries, please reach out to:
Investor Relation
investors@crossject.com

Frequently Asked Questions

What is ZEPIZURE®?

ZEPIZURE® is an emergency treatment for epilepsy crises developed by CROSSJECT, utilizing a needle-free injector for rapid administration.

How has CROSSJECT performed financially in 2024?

The financial report highlights significant growth and the successful acquisition of a $60 million contract with BARDA, emphasizing the company's strong market position.

What other products is CROSSJECT developing?

CROSSJECT is also working on treatments for allergic reactions, adrenal insufficiencies, opioid overdoses, and asthma attacks, showing a commitment to a broad range of medical emergencies.

How can investors connect with CROSSJECT?

Investors can reach out via email at investors@crossject.com for more insights and information regarding the company’s performance and future endeavors.

Where can I find the annual financial report?

The annual financial report for 2024 is available on CROSSJECT's official website, providing comprehensive insights into the company’s financial status and strategic direction.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.